Načítá se...
Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD) NEN of different origin (57 pancreatic NENs (P...
Uloženo v:
| Vydáno v: | Endocr Connect |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Bioscientifica Ltd
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6528409/ https://ncbi.nlm.nih.gov/pubmed/31026812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-19-0134 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|